Israel Englander’s Metagenomi Therapeutics MGX Stock Holding History

Israel Englander’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$136K	Sell	114,025 -56,079	-33%	-$75K	﹤0.01%	5423
2026 Q1	$228K	Sell	170,104 -65,081	-28%	-$101K	﹤0.01%	5123
2025 Q4	$381K	Sell	235,185 -75,507	-24%	-$163K	﹤0.01%	5116
2025 Q3	$736K	Sell	310,692 -72,341	-19%	-$147K	﹤0.01%	4840
2025 Q2	$567K	Buy	383,033 +197,925	+107%	+$310K	﹤0.01%	4820
2025 Q1	$252K	Buy	185,108 +170,699	+1,185%	+$407K	﹤0.01%	5188
2024 Q4	$52K	Sell	14,409 -403,469	-97%	-$973K	﹤0.01%	5586
2024 Q3	$907K	Buy	417,878 +104,716	+33%	+$363K	﹤0.01%	4359
2024 Q2	$1.23M	Sell	313,162 -434,386	-58%	-$2.98M	﹤0.01%	3958
2024 Q1	$7.57M	Buy	+747,548	New	+$8.59M	﹤0.01%	2450

Other funds holding MGX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Israel Englander's MGX Position: Q2 2026 in Review

Israel Englander reduced its Metagenomi Therapeutics (MGX) stake by 33% in Q2 2026, selling an estimated $75K and leaving 114,025 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #5423.

Israel Englander first reported a position in MGX in Q1 2024 and has held it in 10 quarters since. The position peaked at $7.57M in Q1 2024. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

Israel Englander held 114,025 shares of Metagenomi Therapeutics worth $136K as of Q2 2026.
Israel Englander sold 56,079 Metagenomi Therapeutics shares in Q2 2026, an estimated $75K.
Metagenomi Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #5423 holding.
Israel Englander first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 10 quarters since.
Israel Englander's Metagenomi Therapeutics position peaked at $7.57M in Q1 2024.
43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.